{'fraction_non_alphanumeric': 0.02709706078329755, 'fraction_numerical': 0.018731028355667433, 'mean_word_length': 5.0303571428571425, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Effect of Surgical Resection on the Prognosis of Gastric Neuroendocrine Tumors

Carcinoid tumors are known to cause several pathological pictures by the various peptides they produce, providing the continuity of disease. Previously, these tumors had been considered to be biologically and clinically more positively progressing tumors, unlike adenocarcinomas. However, upon the discovery of biological and clinical differences between pulmonary and intestinal carcinoids, these tumors have begun to be evaluated as a special type of a very different tumor family [1].


Introduction
Carcinoid tumors are known to cause several pathological pictures by the various peptides they produce, providing the continuity of disease. Previously, these tumors had been considered to be biologically and clinically more positively progressing tumors, unlike adenocarcinomas. However, upon the discovery of biological and clinical differences between pulmonary and intestinal carcinoids, these tumors have begun to be evaluated as a special type of a very different tumor family [1].
Gastric NETs (Neuroendocrine Tumors) are a type of tumor formed with excessive proliferation of enterochromaffin-like cells (ECL) that are especially localized in the gastric fundus and elevation of plasma gastrin levels, resulting in a series of neoplastic changes [2]. Multiple endocrine neoplasm (MEN-1) syndrome with the secretion of atrophic gastritis or gastrin related with low levels of acid may form the basis for hypergastrinaemia.
Pathophysiologically low acid level, hypergastrinaemia and increased ECL proliferation play a role in development of the disease.
Evaluation of ECL cell proliferation, its histologic characterization, transformation and invasion degree has led to the development of strategies for the treatment of carcinoid tumors of the stomach [3].
In recent years, with the advancements of endoscopic techniques, the frequency of incidental detection of the disease has increased, while the advent of endoscopic resection improves on its treatment. Because of the low incidence of gastric NET in the general population, there is no established diagnosis and treatment algorithm even though there have been several clinical studies.
Guidelines established by the WHO (World Health Organization) are currently used by numerous centers in the diagnosis, treatment and management of this disease.
Gastric NETs are among the rare tumors, accounting for 1% of all neuroendocrine tumors and less than 2% of all gastric tumors [4]. However, recent studies show an increased incidence of gastric carcinoid tumors.
It has been reported in a study examining three national databases that, the incidence of gastric NETs increased to 1.77% from 0.3% from 1950s and increased to 8.7% from 2.4% among all carcinoid tumors [5].
A study using Surveillance, Epidemiology, and End Results (SEER) databases found that, the incidence of gastric NETs raised to 1.7% from 0.2% between 1973 and 1997 [6]. It was found in the same study that, 64% of patients with gastric NET detected were female patients and the incidence of non-carcinoid gastric cancer increased by two-fold in male patients. The reason of this increase in the incidence of gastric NET is not clear. This increase may suggest that gastric NETs are detected more frequently with upper gastrointestinal system endoscopy which has become more widespread, but the biological factors that may trigger the disease cannot be ignored. One of the proposed theories suggest that an increased use of acid-suppressing drugs may cause an increase in hypergastrinema induced carcinoid tumors. As the biology of these tumors are better understood, clinicians will provide more benefits in terms of the diagnosis, prevention and treatment of these disease.
Previously, gastric NETs had been divided into 3 types. However, a new type was recently added, Type-4 Neuroendocrine Carcinoma.
hypergastrinaemia. Chronic atrophic gastritis (CAG) was found to be correlated with the incidence (82%), while 25% of these patients showed ECL cell hyperplasia. These tumors are usually single at the time of diagnosis with a mean diameter greater than 4 cm and they either invaded or exceeded the muscularis propria. These rare tumors are most likely to give late manifestations; in a series, metastasis has been reported in all patients during diagnosis [8,9].
Aggressive cytoreductive surgery is extremely rarely indicated, but gastric resection may be required in order to resolve complications such as hemorrhage, obstruction or perforation.

Prognosis
Outcomes of patients with gastric carcinoid tumors are quite different and especially associated with the subtype of gastric lesion and with the underlying disease. Because the majority (>75%) of gastric carcinoid tumors encountered in the clinical practice have type 1 lesions, outcomes are especially related to this type.
Unfortunately, data collection by Godwin has led to the widespread recognition of the different types of gastric carcinoids. Since his study was conducted before the widespread use of endoscopy, it is necessary to make assessment in favor of more malignant lesions (defined only at surgery or autopsy). It is possible that Godwin's report might not take into account most of the relatively benign type 1 tumors. A more recent analysis by Modlin et al. [10] investigated 204 gastric carcinoid tumor cases obtained from about six thousand carcinoid tumor reports recorded in the SEER database between 1973 and 1991, and found 5-year survival rate as 48.6% for all gastric carcinoids.
5-year survival is 64% for localized lesions [11]. However, neither Godwin nor Modlin et al. [12] have recordings of individual carcinoid subtype for each patient. In a later study by Rappel and colleagues in 1995 on 110 patients with carcinoid tumor of the stomach, survival rate was found to be 78% and when corrected for age, this rate raised to 100% for 88 patients with type 1 lesion.
Based on this data, Rappel concluded that patients with type 1 gastric carcinoid must not experience any change in their natural survival status. Although he outlines this situation as far from reality, in fact this well reflects that generally a benign prognosis should be expected for this subtype of gastric carcinoid tumors. Interestingly, in an update of SEER database by Modlin et al. [12], 5-year survival was considered as 63% for all gastric carcinoids and this rate was found as 69.1% for localized lesions. While a better prognosis is certainly more likely for type-1 non-metastatic small carcinoids showing minimal invasion, the moderate rate in the latter study is somehow unexpected and suggests that these tumors may present more malignant behaviors than previously thought. Furthermore, possible morbidity and mortality that may occur during or after repeated endoscopic resections or removal of these lesions with antrectomy or gastrectomy should be considered. All conclusive discussions should include likelihood of later recurrence of these lesions and potential necessity of additional intervention. Normally life expectancy is optimistic in this patient group, but still there is an impression that the positive outcomes have been presented mostly for the majority of persons with type 1 lesions.
The incidence of metastatic spread related to gastric carcinoids in Zollinger-Ellison syndrome (ZES) is 10% and general prognosis of such gastric carcinoids is similar to type 1 gastric carcinoids [12].
In a recent case report, 38-year survival is reported in a patient with ZES, liver metastasis and gastric carcinoid who has been effectively treated with octreotide [13]. However, in general, longterm prognosis of type 2 disease ultimately reflects the course of MEN-1 gastrinoma (5-year survival rate: 60-75%) [14]. The overall results table for sporadic gastric carcinoid tumors is poor compared to only ECL cell derived lesions or hypergastrinaemia. Five-year survival rate is directly associated with the degree of metastasis in less than 50% of such lesions [15][16][17].

Objective
The objective of this study is to perform a survival analysis in line with the WHO 2010 staging system in patients undergone surgical resection in our clinic with the diagnosis of Gastric NET and to investigate pathological factors affecting prognosis.

Materials & Methods
The data of 27 patients who underwent surgical resection in  Looking to the localization of gastric NETs, it was found that gastric NET was localized in the corpus in 10 (37%) patients, in the fundus in 8 (29.6%) patients, in the antrum in 5 (18.5%) patients and in the cardia in 4 (14,8%) patients.
When the patients were clinically and pathologically classified according to gastric NET classification, 15 patients (55.6%) were found to have type 1, 5 (18.5%) type 3 and 7 (25.9%) type 4-NEC disease. There were no patients found in the type 2 group associated with ZES and MEN 1.  In this study, no statistically significant difference was found related to prognosis in terms of tumor diameter, but we see that tumor diameters were greater than 3 cm in 5 patients who exited.
Because of the lack of standardized evaluations in our clinic, the number of mitoses was not included in our study.
Although death is reported infrequently in patients with a tumor diameter under 2 cm, recently total gastrectomy has been recommended in these patients. However, recent studies have demonstrated that endoscopic excision can be safely performed in the lesions smaller than 1 cm in type 1 and type 2 gastric NETs.
Antrectomy can be used together with excision of the accessible lesions with a tumor diameter greater than 1 cm [18]. Lymph node metastasis is reported as 5% for type 1, 30% for type 2 and 71% for type 3 gastric NETs, while especially liver metastasis, distant organ metastasis is seen by 2.5%, 10% and 69%, respectively [18]. In our study, rate of lymph node metastasis was found as 13% for Type 1, 75% for Type 3 and 57% for NEC. to the muscularis propria and beyond, tumor diameter being greater than 1 cm, vascular invasion, presentation with endocrine syndrome, high mitotic activity and being sporadic [18]. In the present study, lack of gastric NET has been shown to be associated with MEN1 and ZES is a lacking aspect in terms of the evaluation of endocrine syndrome. in NECs, considering as adenocarcinomas of the stomach [3,18].
Similarly, in the present study we see that NEC patients have a poor prognosis with 57% mortality.
In a case series by Güler and Erikoğlu [19] in 2003, the results of 5 patients with Type-1 multiple gastric carcinoid between 1996 and 2001 were presented. The authors argued the necessity of total gastrectomy and lymph node dissection in multiple gastric carcinoids.
Until recently, total gastric resection has been recommended as the only surgical option for the treatment of gastric carcinoid tumors. In recent years, antrectomy which is a less aggressive method and proven to return elevated gastrin levels to normal has been recommended [20]. Wangberg [21] demonstrated that, even if hypergastrinaemia is reversed by removal of the antrum, enterochromaffin-like cell hyperplasia which occurs after a certain step is irreversible. In accordance with recent studies, in our study only 7 patients undergone Wedge resections maintained their disease-free survivals, showing that antrectomy may not be necessary.
Kımıloğlu et al. [22] evaluated tumor markers such as Ki-67, CD-117 and p53, and performed a survival analysis and found that the Ki-67 value was significant in prediction of prognosis. Similarly, in the present study we found that the prognosis of tumor was worse and the chance of lymph node metastasis was significantly different in high Ki-67 values.
Antrectomy should be performed at the hyperplastic stage especially before invasive carcinoid tumor is arisen. Gastrin levels return to normal only in half of gastric NET patients, while endoscopic follow-up continues in the other half. It is obvious that, a careful monitoring with gastroscopy and fundus biopsy will be necessary for as long as stomach tissue is left. Whereas, subtotal or total gastrectomy will be needed for locally invasive and metastatic tumors such as a wide primary lesion which presents nodular hyperplasia. The lesion should be excised in the cases of regional lymph node metastasis. Since sporadic NETs behave aggressively, their treatment is surgery. Lymph node dissection is recommended in addition to surgery if the tumor size is greater than 2 cm [16].
Unlike results found in the literature, in this study we achieved good survival outcomes only with WR in early-stage tumors.

Conclusion
In the present study, prognostic factors were examined in 27 patients with gastric NETs that are frequently encountered and significant results were obtained especially related to Ki-67. We presented what is done in our clinics regarding gastric NETs that have no sharp limits for treatment. In conclusion, according to the data of our clinic, a Ki-67 value which could be preoperatively assessed with an endoscopic biopsy above 9.5 may be a suggestion for lymph node dissection for gastric NETs.
The limiting factors of this study that may confound our statistical analysis include the limited number of patients, the fact that different parameters had been assessed by pathology over the many years from which patient data had been taken and the unevenly distributed stages and gastric NET types between patients.